ALANINE AMINOTRANSFERASE LEVELS AND MONOCYTE COUNT INDEPENDENTLY PREDICT 30-DAY OUTCOMES IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS WITH SUCCESSFULLY RESTORED CORONARY TIMI-3 FLOW BY PRIMARY PERCUTANEOUS CORONARY INTERVENTION

Year 2014, Volume: 16 Issue: 1, 29 - 34, 01.03.2014

Mustafa Çetin Sinan Altan Kocaman Murtaza Emre Durakoğlugil Aytun Çanga Yüksel Çiçek Özgür Akgül Mehmet Gül Turan Erdoğan

Abstract

Aim: To investigate the relationship of various hematological and biochemical parametersbesides the cardiac enzymes with 30-day outcomes in patients with successfully restoredcoronary TIMI-3 flow by primary percutaneous coronary intervention (p-PCI).Materials and methods: Two hundred patients with ST elevation myocardial infarction(STEMI), with no history of prior myocardial infarction (MI), who underwent p-PCI and hadTIMI-3 flow, were enrolled, consecutively. The primary endpoint of the study was defined asthe composite of death, fatal and non-fatal MI, target vessel revascularization andcerebrovascular event.Results: Only ALT concentration (OR: 1.010, 95% CI: 1.003-1.018, P = 0.008), monocytecount (OR: 1.002, 95% CI: 1.001 - 1.004, P = 0.005), hypertension (OR: 3.010, 95% CI: 1.081- 8.384, p = 0.035) and lower LVEF (OR: 0.926, 95% CI: 0.875 - 0.981, P = 0.008) wereindependent predictors of primary endpoint in multivariate logistic regression analysis.Conclusion: We found that elevated liver enzymes as determined by serum Alanineaminotransferase levels and monocyte count as well as hypertension and lower LVEFindependently predicted 30-day outcomes in patients with successfully restored coronary flowby p-PCI. These parameters may provide new aspects, to identify the pathophysiology andprognosis of acute vascular events, which in turn may facilitate discovery of new treatmentmodalities

Keywords

STEMI, Liver enzymes, Alanine aminotransferase, Monocyte count, Primary PCI, Major adverse cardiac events

Alanin Aminotransferaz Düzeyleri ve Monosit Sayısı Primer Perkutan Koroner Girişim ile Başarılı TIMI-3 Koroner Akım Sağlanan ST Yükselmeli Miyokard İnfarktüsünde 30 Günlük Sonuçları Bağımsız Olarak Öngörür

Abstract

Amaç: Primer perkutan koroner girişim (p-PKG) ile başarılı TIMI-3 koroner akım sağlananhastalarda 30 günlük sonuçlar ile kardiyak enzimlerin yanında değişik hematolojik vebiyokimyasal parametreler arasındaki ilişkinin araştırılması amaçlandı.Materyal ve metod: Çalışmaya daha önceden miyokard infarktüsü geçirmeyen, p-PKGuygulanan ve TIMI-3 koroner akım sağlanan ST yükselmeli miyokart enfarktüslü (STYMI) 200hasta alındı. Çalışmanın birincil son noktası bileşik ölüm, ölümcül ve ölümcül olmayanmiyokard infarktüsü, hedef damara tekrar girişim ve serebrovasküler olaydı. Bulgular: Çok değişkenli analizde birincil son noktanın bağımsız öngörücüleri olarak sadecealanin aminotransferaz konsantrasyonu (OR: 1.010, 95% CI: 1.003-1.018, P = 0.008), monositsayısı (OR: 1.002, 95% CI: 1.001 - 1.004, P = 0.005), hipertansiyon (OR: 3.010, 95% CI: 1.081- 8.384, p = 0.035) ve düşük sol ventrikül ejeksiyon fraksiyonu (OR: 0.926, 95% CI: 0.875 0.981, P = 0.008) bulundu.Sonuç: Hipertansiyon ve düşük sol ventrikül ejeksiyon fraksiyonu kadar serum alaninaminotransferaz düzeyi olarak tanımlanan yükselmiş karaciğer enzimleri ve monosit sayısı pPKG ile başarılı koroner akım sağlanan hastalarda 30 günlük sonuçları bağımsız olarak öngördü.Bu parametreler akut vasküler olayların patofizyolojisini ve prognozunu anlamak için yeni bakışaçısı sağlayabilir.Bu da yeni tedavi seçeneklerinin bulunmasını kolaylaştırabilir

Keywords

Miyokart enfarktüsü, Karaciğer enzimleri, Alanin aminotransferaz, Monosit sayısı, Primer PKG, Major istenmeyen kardiyak olaylar

References

• Figueras J, Ferreira-Gonzalez I, Rizzo M, Alcalde O, Barrabes JA, Domingo E, et al. High incidence of TIMI flow 0 to I in patients with ST-elevation myocardial infarction without electrocardiographic lytic criteria. Am Heart J. 2009;158:1011- 7.
• Kushner FG, Hand M, Smith SC, Jr., King SB, 3rd, Anderson JL, Antman EM, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation.
• Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909-45.
• Killip T, 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457-64.
• Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102:2031-7.
• The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985;312:932- 6.
• Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation. 2007;116:2634-53.
• Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation. 2004;110:e506-10.
• Gibson CM, Karha J, Murphy SA, James D, Morrow DA, Cannon CP, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003;42:7-16.
• Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-51.
• Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74:2527-34.
• Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med. 2007;204:3037-47.
• Weihrauch D, Zimmermann R, Arras M, Schaper J. Expression of extracellular matrix proteins and the role of fibroblasts and macrophages in repair processes in ischemic porcine myocardium. Cell Mol Biol Res. 1994;40:105-16.
• Trial J, Baughn RE, Wygant JN, McIntyre BW, Birdsall HH, Youker KA, et al. Fibronectin fragments modulate monocyte VLA-5 expression and monocyte migration. J Clin Invest. 1999;104:419-30.
• Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res. 1985;57:84-95.
• Pfeffer MA, Pfeffer JM. Ventricular enlargement and reduced survival 1987;75:IV93-7. infarction. Circulation.
• Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981-8.
• Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161-72.
• Nahrendorf M, Wiesmann F, Hiller KH, Hu K, Waller C, Ruff J, et al. Serial cine-magnetic resonance imaging of left ventricular remodeling after myocardial infarction in rats. J Magn Reson Imaging. 2001;14:547-55.
• Tsujioka H, Imanishi T, Ikejima H, Tanimoto T, Kuroi A, Kashiwagi M, et al. Post-reperfusion enhancement of CD14(+)CD16(-) monocytes and microvascular obstruction in ST-segment elevation acute myocardial infarction. Circ J. 2010;74:1175-82.
• Liu Y, Imanishi T, Ikejima H, Tsujioka H, Ozaki Y, Kuroi A, et al. Association between circulating monocyte subsets and in- stent restenosis after coronary stent implantation in patients with ST-elevation myocardial infarction. Circ J. 2010;74:2585- 91.
• Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533-7.
• Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001;38:1002-6.
• Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem. 2000;46:2050-68.
• Lazzeri C, Valente S, Tarquini R, Chiostri M, Picariello C, Gensini GF. Prognostic values of admission transaminases in ST-elevation myocardial infarction submitted to primary angioplasty. Med Sci Monit. 2010;16:CR567-74.
• Lofthus DM, Stevens SR, Armstrong PW, Granger CB, Mahaffey KW. Pattern of liver enzyme elevations in acute ST- elevation myocardial infarction. Coron Artery Dis. 2012;23:22-30.
• Allen LA, Felker GM, Pocock S, McMurray JJ, Pfeffer MA, Swedberg K, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009;11:170-7.
• Seeto RK, Fenn B, Rockey DC. Ischemic hepatitis: clinical presentation and pathogenesis. Am J Med. 2000;109:109-13.
• Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. Am Heart J. 2000;140:111-20.
• Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis. 2002;6:947-67, viii-ix.
• Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C- reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. Jama.
• Zairis MN, Manousakis SJ, Stefanidis AS, Papadaki OA, Andrikopoulos GK, Olympios CD, et al. C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction. Am Heart J. 2002;144:782-9.
• Meisinger C, Heier M, von Scheidt W, Kuch B. Admission C- reactive protein and short- as well as long-term mortality in diabetic versus non-diabetic patients with incident myocardial infarction. Clin Res Cardiol. 2010;99:817-23.
• Mason JE, Starke RD, Van Kirk JE. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol. 2010;13:36-41.
• Paolicchi A, Minotti G, Tonarelli P, Tongiani R, De Cesare D, Mezzetti A, et al. Gamma-glutamyl transpeptidase-dependent iron reduction and LDL oxidation--a potential mechanism in atherosclerosis. J Investig Med. 1999;47:151-60.
• Emdin M, Pompella A, Paolicchi A. Gamma- glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation. 2005;112:2078-80.
• Karlson BW, Wiklund O, Hallgren P, Sjolin M, Lindqvist J, Herlitz J. Ten-year mortality amongst patients with a very small or unconfirmed acute myocardial infarction in relation to clinical history, metabolic screening and signs of myocardial ischaemia. J Intern Med. 2000;247:449-56.
• Emdin M, Passino C, Michelassi C, Titta F, L'Abbate A, Donato L, et al. Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction. Eur Heart J. 2001;22:1802-7.
• Breitling LP, Grandi NC, Hahmann H, Wusten B, Rothenbacher D, Brenner H. Gamma-glutamyltransferase and prognosis in patients with stable coronary heart disease followed over 8 years. Atherosclerosis. 2010;210:649-55.
• Stojakovic T, Scharnagl H, Trauner M, Pieske B, Wellnitz B, Seelhorst U, et al. Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-The Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis. 2010;208:564-71.
• Lazzeri C, Valente S, Tarquini R, Chiostri M, Picariello C, Gensini glutamyltransferase activity in non-diabetic ST-elevation myocardial infarction. Intern Emerg Med. 2011;6:213-9.
• Dogan A, Icli A, Aksoy F, Varol E, Erdogan D, Ozaydin M, et al. Gamma-glutamyltransferase in acute coronary syndrome patients without ST elevation and its association with stenotic lesion and cardiac events. Coron Artery Dis. 2012;23:39-44.
• Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet. 1991;338:1409- 11.